Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Stimulation of Peripheral Afferents to Reduce Muscle Inhibition at the Knee (SPARK)

15 settembre 2026 aggiornato da: Northeastern University

Knee osteoarthritis is a leading cause of disability, and the muscle weakness that limits walking in this population arises not only from the joint itself but from afferent signals that inhibit motor drive to the thigh muscle, which is why exercise alone so often produces incomplete recovery. This project examines whether brief, non-invasive electrical stimulation of a nerve behind the knee can reduce inhibition and restore muscle coordination while walking in adults with knee osteoarthritis. Establishing this effect would identify a modifiable neural target that current rehabilitation does not address, with the potential to improve physical function and independence for the millions of adults living with this condition.

Panoramica dello studio

Descrizione dettagliata

Knee osteoarthritis affects more than 14 million adults in the United States and is a leading cause of disability. Its most disabling consequence is not joint degeneration alone but persistent quadriceps dysfunction. Afferent signals arising from the painful joint inhibit the descending motor drive that activates the muscle, so voluntary activation remains incomplete. Exercise therapy, the mainstay of care, therefore produces strength gains of only 10 to 20 percent against the 30 to 40 percent required for meaningful clinical benefit, and patients walk with rigid, co-contracted movement patterns that concentrate joint loading and accelerate degeneration. Existing interventions address either pain or motor retraining; none target the cortical circuits in which the two interact. This study tests whether paired-pulse electrical stimulation (ppES) of the tibial nerve can reduce that inhibition. ppES delivers two stimuli in rapid succession: the first activates sensory afferents projecting to the primary somatosensory cortex, and the second, delivered at a precisely timed interval, induces heterosynaptic depression of that transmission, in turn reducing sensory-driven inhibition of motor output. Applied at the tibial nerve, ppES acts on the sensorimotor integration that governs quadriceps activation during walking. Twenty adults with knee osteoarthritis will each complete two single-session visits separated by at least seven days, receiving active ppES at one visit and sham stimulation at the other in randomized order, with participants and outcome assessors blinded. At each visit, before intervention and again immediately and 30 minutes afterward, we will measure short-latency afferent inhibition of the quadriceps motor pathway and quadriceps-hamstrings co-contraction during treadmill walking, the two primary outcomes. Somatosensory evoked potentials and modular organization of gait will be measured as secondary outcomes. Aim 1 will determine whether ppES reduces sensorimotor inhibition and co-contraction relative to sham. Aim 2 will determine whether baseline pain sensitization, cortical sensory processing, and sensorimotor inhibition predict the magnitude and variability of individual response. Establishing that this circuit is modifiable would identify a rehabilitation target that current care does not address and would provide the mechanistic evidence and effect-size estimates required for a trial of ppES as an adjunct to exercise.

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

45 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • >45 years old

  • Able to speak and understand English

  • Unilateral or bilateral knee OA, per NICE criteria

    • Age 45+ AND
    • Have activity-related joint pain AND
    • Have either no morning joint-related stiffness or morning stiffness that lasts no longer than 30 minutes
  • Score > 3/20 on WOMAC pain scale

  • If using pain medications, report >4 weeks of stable use without recent adjustments

Exclusion Criteria:

  • History of lower extremity surgery.

  • BMI > 40kg/m^2

  • Received an intra-articular knee joint injection within the last 3 months.

  • Currently pregnant.

  • Currently experiencing heavy menstruation, within one month of an IUD contraceptive device (e.g. coil) being fitted or within 6 weeks after giving birth or at least three months after having a Caesarean.

  • Suspected or diagnosed heart problems (e.g. arrhythmia, cardiac disturbances).

  • Use of an implanted electronic device (e.g. a cardiac pacemaker or defibrillator).

  • Insulin-dependent diabetes.

  • Implants in the lower limb.

  • Suspected or diagnosed epilepsy or a familial history of epilepsy.

  • History of neurologic or psychiatric condition (e.g. Parkinson's disease, bipolar disorder, epilepsy, etc)

  • Implanted cardiac pacemaker, cochlear implant, medication pump, surgical clips or other metal (dental implants excluded).

  • Use of alcohol or recreational drugs in the prior 12 hours.

  • Frequent or severe headaches.

  • Prior adverse reaction to transcranial magnetic stimulation.

  • Altered sensation (hypo or hypersensitivity) of the skin of the thigh.

  • Swollen, infected, inflamed, or damaged skin of the thigh.

  • Current Use of prescription and over the counter medications will be grounds for exclusion except for:

    • Contraceptive (birth control) drugs (e.g. those containing ethinyl estradiol and/or norethindrone).
    • Seasonal allergy medications (e.g. cetirizine (Zyrtec), fexofenadine (Allegra), and loratadine (Claritin)).
    • Antihypertensives
    • Statins
    • GLP-1 agonists
    • Non-insulin diabetes medications (metformin)
    • Thyroid medications
    • Osteoporosis medications
    • Respiratory medications
    • Pain medications available over the counter (ibuprofen, acetaminophen, etc)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Paired-Pulse Electrical Stimulation Intervention

Participants will receive a single session intervention of pairs of electrical stimulation pulses delivered to the tibial nerve. These pairs will use pulses of 1000 microseconds duration, separated by a 5 millisecond interstimulus interval, delivered at a frequency of 10Hz. Participants will receive 12,000 stimulation pairs during an intervention lasting approximately 30 minutes.

Comparatore fittizio: Peripheral Electrical Stimulation

Participants will receive a single session intervention of single pulses of electrical stimulation to the tibial nerve at a below motor threshold intensity. These pulses will be delivered with a pulse width of 1000 microseconds, delivered at 20 Hz frequency. This intervention will last approximately 30 minutes and deliver 24,000 stimulation pulses.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Short-latency Afferent Inhibition Ratio
Lasso di tempo: Before, immediately after, and 30 minutes after intervention at each study session

Measuring change in short-latency afferent inhibition (SAI) ratio of the motor cortex controlling quadriceps muscle excitability across timepoints

Before, immediately after, and 30 minutes after intervention at each study session
Change in Muscle Co-Activation Percentage During Treadmill Walking
Lasso di tempo: Before, immediately after, and 30 minutes after intervention at each study session

Measuring change in co-activation percentage of quadriceps and hamstring muscle pairs during treadmill walking across timepoints

Before, immediately after, and 30 minutes after intervention at each study session

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Somatosensory Evoked Potentials Amplitude
Lasso di tempo: Before, immediately after, and 30 minutes after intervention at each study session

Measuring change in somatosensory evoked potentials (SEPs) amplitude measured in the sensory cortex in response to peripheral electrical stimulation across timepoints

Before, immediately after, and 30 minutes after intervention at each study session
Change in Dynamic Motor Control Index of Gait During Treadmill Walking
Lasso di tempo: Before, immediately after, and 30 minutes after intervention at each study session

Measuring change in the organization of motor control strategies, in terms of dynamic motor control index, during treadmill walking across timepoints

Before, immediately after, and 30 minutes after intervention at each study session

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 settembre 2026

Completamento primario (Stimato)

1 settembre 2027

Completamento dello studio (Stimato)

1 settembre 2027

Date di iscrizione allo studio

Primo inviato

3 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 settembre 2026

Primo Inserito (Effettivo)

22 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi